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Abstract
Background: Coordinated chondrocyte proliferation and differentiation are required for normal
endochondral bone growth. Transcription factors binding to the cyclicAMP response element
(CRE) are known to regulate these processes. One member of this family, Activating Tanscription
Factor 3 (ATF3), is expressed during skeletogenesis and acts as a transcriptional repressor, but the
function of this protein in chondrogenesis is unknown.
Results:  Here we demonstrate that Atf3  mRNA levels increase during mouse chondrocyte
differentiation in vitro and in vivo. In addition, Atf3 mRNA levels are increased in response to
cytochalasin D treatment, an inducer of chondrocyte maturation. This is accompanied by increased
Atf3  promoter activity in cytochalasin D-treated chondrocytes. We had shown earlier that
transcription of the cell cycle genes cyclin D1 and cyclin A in chondrocytes is dependent on CREs.
Here we demonstrate that overexpression of ATF3 in primary mouse chondrocytes results in
reduced transcription of both genes, as well as decreased activity of a CRE reporter plasmid.
Repression of cyclin A transcription by ATF3 required the CRE in the cyclin A promoter. In parallel,
ATF3 overexpression reduces the activity of a SOX9-dependent promoter and increases the
activity of a RUNX2-dependent promoter.
Conclusion:  Our data suggest that transcriptional induction of the Atf3  gene in maturing
chondrocytes results in down-regulation of cyclin D1 and cyclin A expression as well as activation
of RUNX2-dependent transcription. Therefore, ATF3 induction appears to facilitate cell cycle exit
and terminal differentiation of chondrocytes.
Background
Growth and development of endochondral bones is con-
trolled through the highly coordinated proliferation and
differentiation of growth plate chondrocytes [1-3]. These
processes are regulated by a large number of endocrine,
paracrine and autocrine hormones and growth factors
that, to a large part, act on chondrocyte cell surface recep-
tors. The intracellular signaling pathways mediating these
effects are not completely understood; however, over the
last 10 years many of the key transcriptional regulators of
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chondrocyte differentiation have been identified. The
Sox9 gene is required for the differentiation of mesenchy-
mal precursor cells to chondrocytes and, together with the
related L-Sox5 and Sox6 proteins, controls chondrocyte-
specific gene expression [4,5]. Sox9 also inhibits terminal
differentiation of chondrocytes to the hypertrophic phe-
notype [6]. In contrast, the Runx2 gene (also known as
Cbfa1) is essential for differentiation of osteoblasts, but
also promotes hypertrophic chondrocyte differentiation
[5,7].
In addition to these key regulators of chondrocyte matu-
ration, numerous other transcription factors have been
implicated in this process. One example is the activating
transcription factor/cyclicAMP response element-binding
protein (ATF/CREB) family that is defined by the ability of
its members to bind to the cyclicAMP response element
(CRE) in target promoters. Mice with inactivation of the
Atf2  gene display chondrodysplasia and reduced
chondrocyte proliferation [8], a similar phenotype to
transgenic mice overexpressing a dominant-negative form
of CREB in cartilage [9]. We and others have shown that
ATF2 and CREB regulate the transcription of the cell cycle
genes cyclin D1 and cyclin A in chondrocytes through
CRE-dependent mechanisms [10-15]. However, the ATF/
CREB family contains additional members [16,17], some
of which (such as ATF3) act as transcriptional repressors.
These repressors could down-regulate CRE-dependent
transcription and thus cause delay of cell cycle progres-
sion and/or promote cell cycle exit during terminal differ-
entiation.
Atf3 expression has been shown to be induced by a large
variety of cellular stresses, including radiation, DNA-dam-
aging agents, adenoviral infection and others [18-22].
Recent evidence also suggests induction of ATF3 by a
number of physiological stimuli such as growth hormone
[23], transforming growth factor β[24] and ligands for
several G-protein-coupled receptors [25]. In some
instances (e.g. in certain heterodimers with other proteins
or certain isoforms of ATF3), ATF3 has been shown to acti-
vate transcription [26,27]. However, in most cases ATF3
has been found to repress transcription of target genes
[17]. Similarly, the effects of ATF3 on cellular physiology
appear to be very context- and cell type-dependent; for
example, ATF3 has been shown to both promote [27-29]
and inhibit [21,30,31] cellular proliferation and cell cycle
progression, and to have both pro- and anti-apoptotic
effects [31,32].
We recently performed microarray analyses of an in vitro
system of mouse chondrocyte differentiation in three-
dimensional micromass cultures [33]. We now extended
these studies and demonstrated that numerous ATF/CREB
family members are expressed in chondrocytes. Most
notably, ATF3 expression is markedly upregulated during
chondrocyte differentiation. Validation of ATF3 expres-
sion and functional studies strongly suggest an important
role for ATF3 in cell cycle exit and terminal differentiation.
Results
Atf3 mRNA levels increase during chondrocyte 
differentiation
Based on the prominent role of ATF2 (gene name Atf2)
and CREB (Creb1) in cartilage development, we analyzed
the expression of ATF-CREB family members in our tran-
scriptional profiles of differentiating micromass cultures
[33]. Numerous family members were expressed during
micromass differentiation (Table 1). Most genes, includ-
ing Atf2 and Creb1, did not display marked changes in
Table 1: Microarray Expression Profiles of ATF/CREB Family Members
Normalized Signal Intensity Values
Genbank Gene Symbol Day 3 Day 6 Day 9 Day 12 Day 15
NM_007497 Atf1 0.62 0.87 1.13 1.27 1.158
BM119623 Atf2 1.10 0.95 0.98 1.00 0.91
BC019946 Atf3 0.84 0.42 0.96 3.40 3.92
AV314773 Atf4 0.99 0.87 1.03 1.42 1.03
AF375476 Atf5 0.40 0.74 1.16 2.54 1.735
AV270913 Atf6 0.74 0.73 1.01 1.75 1.818
BC026483 Atf7 1.09 1.07 0.95 1.08 0.875
NM_016767 Batf 0.90 0.97 1.01 1.04 1.058
NM_009952 Creb1 1.17 0.88 0.76 0.77 0.77
BG070002 Creb3 0.97 1.07 1.00 0.99 0.94
BC013534 Crebl1 1.58 1.21 1.01 0.91 0.860
BC016447 Creb3l1 0.30 0.71 1.09 1.34 1.037
BC010786 Creb3l3 0.94 1.03 1.15 0.99 1.002
BC022605 Creb3l4 0.92 0.93 1.08 0.86 0.862
AI467599 Crem 1.21 1.09 0.90 0.79 0.890BMC Molecular Biology 2006, 7:30 http://www.biomedcentral.com/1471-2199/7/30
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expression during micromass differentiation, and no
genes were down-regulated two-fold or more. However,
Atf3, Atf5, Atf6 and Creb3l1 genes displayed upregulation
towards the end of the time course. The strongest effects
were observed for Atf3 transcript levels that increased 4.7-
fold from day 3 to 15 of micromass culture (Fig. 1A). Atf5,
Atf6 and Creb3l1 mRNA levels increased 4.3-, 2.5- and 3.5-
fold over the same period, respectively. Because it showed
the largest increase, we focused subsequent studies on the
Atf3 gene. We performed real-time PCR analyses of inde-
pendent micromass cultures from mouse embryonic limb
bud cells and demonstrated a strong increase of Atf3
mRNA expression during micromass differentiation, thus
validating the microarray data (Fig. 1B).
To examine the expression of Atf3 during chondrocyte dif-
ferentiation in vivo, we dissected tibiae from embryonic
day 15.5 CD1 mice into the resting/proliferating, pre-
hypertrophic and hypertrophic areas (at this stage, CD1
tibiae are not vascularized yet; the center of the bone is
thus still comprised of hypertrophic cartilage). RNA was
directly isolated from dissected tibiae, without subcultur-
ing of cells. Real-time PCR analyses demonstrated expres-
sion of collagen II (Col2a1) in the resting/proliferating
area that declines significantly in the prehypertrophic and
hypertrophic areas (Fig. 2A). In contrast, collagen X
(Col10a1) mRNA was virtually undetectable in the rest-
ing/proliferating area and increased strongly in the other
zones (Fig. 2B). These expression profiles of known mark-
ers of early and late chondrocyte differentiation con-
firmed efficient separation of the different growth pate
zones by microdissection. Atf3  mRNA levels increased
more than five-fold from the resting/proliferating to the
hypertrophic zone (Fig. 2C). Atf3  expression thus dis-
played a similar pattern as Col10a1, although the induc-
tion was less pronounced for Atf3.
Atf3 is upregulated by cytochalasin D, an inhibitor of actin 
polymerization
We had shown earlier that inhibition of actin polymeriza-
tion by cytochalasin D promotes chondrogenic differenti-
ation [34,35]. Thus, we examined whether cytochalasin D
affects  Atf3  expression. Indeed, incubation of primary
chondrocytes with cytochalasin D caused a more than 30-
fold induction of Atf3 mRNA levels (Fig. 3A). To examine
whether this upregulation is due to transcriptional effects,
primary chondrocytes were transfected with an Atf3 pro-
moter – firefly luciferase construct. Cytochalasin D treat-
ment resulted in five-fold upregulation of Atf3 promoter
activity (Fig. 3B). Thus, cytochalasin D induces Atf3
through transcriptional mechanisms, at least in part.
ATF3 represses SOX9-dependent and increases RUNX2-
dependent transcription
We next asked whether increased expression of Atf3 affects
chondrocyte-specific gene expression. Primary chondro-
cytes were cotransfected with reporter vectors for SOX9
and RUNX2 activity and an ATF3 expression vector. Over-
expression of ATF3 resulted in an approximately 40 %
reduction in SOX9-dependent transcription (Fig. 4A) and
an 80 % increase in RUNX2-dependent transcription (Fig.
4B), suggesting that upregulation of ATF3 can promote
the transition from proliferating to hypertrophic chondro-
cytes.
Atf3 expression is upregulated during chondrocyte differenti- ation in vitro Figure 1
Atf3 expression is upregulated during chondrocyte 
differentiation in vitro. Atf3 mRNA expression during 
chondrogenic differentiation of mouse embryonic limb bud 
cells in micromass culture was examined by microarray (A) 
and real-time PCR (B) analyses (different cell isolations were 
used for the experiments in A and B). Microarray data sets 
represent averages from three independent experiments. 
Real-time data were normalized to Gapdh levels and present 
average and SEM from four independent experiments. Both 
approaches show similar expression patterns with a strong 
increase in Atf3 expression during micromass differentiation.
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Atf3 expression is upregulated during chondrocyte differentiation in vivo Figure 2
Atf3 expression is upregulated during chondrocyte differentiation in vivo. Tibia isolated from embryonic day 15.5. 
mice were microdissected into the resting/proliferating, prehypertrophic and hypertrophic areas, and RNA was isolated 
directly out of cartilage. Expression of type II collagen II (Col2a1), type X collagen (Col10a1) and Atf3 was examined by real-time 
PCR analyses and normalized to Gapdh expression. All data represent averages and SEM from four independent experiments 
(*: p < 0.05). Col2a1 was strongly expressed in the resting/proliferating area and declined subsequently (A). Col10a1 was virtu-
ally undetectable in the resting/proliferating area and strongly induced in the prehypertrophic and hypertrophic areas (B). Atf3 
was already expressed in the resting/proliferating area, but expression was significantly increased in the more mature zones of 
the growth plate.
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ATF3 represses transcription of the cyclin D1 and cyclinA 
genes
ATF3 acts as a transcriptional repressor through the CRE.
We had demonstrated a requirement for the CRE for max-
imal activity of the cyclin D1 and cyclin A promoters in
chondrocytes [11,12,14,15]. We thus examined the effects
of ATF3 overexpression on CRE-dependent transcription
and the activity of these two cyclin promoters. Transient
transfection of an ATF3 expression plasmid decreased the
activity of the CRE-dependent reporter by approximately
50 % (Fig. 5A) and cyclin D1 promoter activity by 38 %
(Fig. 5B). ATF3 overexpression most strongly repressed
cyclin A promoter activity which decreased to less than
10% of control values (Fig. 5C). To determine whether the
effects of ATF3 on cyclin A transcription were mediated by
the CRE, we performed parallel experiments using a cyclin
A promoter construct with a mutated CRE (Fig. 5C). ATF3
overexpression did not affect activity of this promoter
fragment, suggesting that ATF3 represses cyclin A tran-
scription directly through the CRE.
Discussion
This study is the first to demonstrate an important role of
ATF3 in the control of endochondral bone growth and
skeletal development. Our data demonstrate upregulation
ATF3 suppresses Sox9-dependent transcription and stimu- lates Runx2-dependent transcription Figure 4
ATF3 suppresses Sox9-dependent transcription and 
stimulates Runx2-dependent transcription. Primary 
chondrocytes were cotransfected with SOX9 (A) or RUNX2 
(B) reporter plasmids, pcDNA3 (control) or an ATF3 
expression vector, and pRLCMV. 24 hours after transfection, 
cells were harvested, firefly luciferase activity was measured 
and normalized to Renilla luciferase activity. Data represent 
averages and SEM from three independent experiments, per-
formed in quadruplicate each (*: p < 0.05). ATF3 overexpres-
sion suppressed SOX9-dependent transcription and 
stimulated RUNX2-dependent transcription.
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Inhibition of actin polymerization induces Atf3 expression  through transcriptional mechanisms Figure 3
Inhibition of actin polymerization induces Atf3 
expression through transcriptional mechanisms. A) 
Primary chondrocytes were cultured for 24 hours with 
DMSO (control) or 1 μM cytochalasin D before harvest and 
RNA isolation. Real-time PCR demonstrated marked induc-
tion of Atf3 mRNA levels by cytochalasin D. Data represent 
averages and SEM from three independent experiments, nor-
malized to Gapdh (*: p < 0.05). B) Primary chondrocytes 
were transfected with an Atf3 promoter plasmid and pRL-
CMV, followed by incubation for 24 hours with DMSO (con-
trol) or 1 μM cytochalasin D. Cells were then harvested, 
firefly luciferase activity was measured and normalized to 
Renilla luciferase activity. Data represent averages and SEM 
from three independent experiments, performed in quadru-
plicate each (*: p < 0.05). Cytochalasin D induced Atf3 pro-
moter activity.
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ATF3 suppresses CRE-dependent transcription Figure 5
ATF3 suppresses CRE-dependent transcription. Primary chondrocytes were cotransfected with a CRE reporter (A), a 
cyclin D1 promoter (-1745CD1LUC, B) or cyclin A promoter plasmids (p707cycAluc and p707cycAlucMut; C), pcDNA3 (con-
trol) or an ATF3 expression vector, and pRLCMV. 24 hours after transfection, cells were harvested, firefly luciferase activity 
was measured and normalized to Renilla luciferase activity. Data represent averages and SEM from three independent experi-
ments, performed in quadruplicate each (*: p < 0.05). ATF3 overexpression suppressed the CRE reporter, cyclin D1 and cyclin 
A wild type promoters significantly, whereas the mutant cyclin A construct showed no response to ATF3 overexpression.







9HFWRU $7)
5
H
O
D
W
L
Y
H

/
L
J
K
W

8
Q
L
W
V


&
&5(GHSHQGHQW5HSRUWHU
&\FOLQ'3URPRWHU
$







9HFWRU $7)
5
H
O
D
W
L
Y
H

/
L
J
K
W

8
Q
L
W
V


%
&\FOLQ$3URPRWHU
5
H
O
D
W
L
Y
H

/
L
J
K
W

8
Q
L
W
V










&\FOLQ$
$7)
&\FOLQ$PXW
9HFWRU
&\FOLQ$PXW
$7)
&\FOLQ$
9HFWRUBMC Molecular Biology 2006, 7:30 http://www.biomedcentral.com/1471-2199/7/30
Page 7 of 11
(page number not for citation purposes)
of Atf3 during chondrogenic differentiation in vivo and in
vitro. Atf3 expression is known to be induced by a number
of different cellular stressors, including hypoxia [22].
Hypoxia has been demonstrated in the cartilage growth
plate in vivo [36], raising the possibility that low oxygen
tension is one of the physiological inducers of ATF3 in
developing cartilage. Interestingly, two of the other ATF/
CREB family members found to be upregulated in our
studies, ATF6 and CREB3L1 (also known as OASIS), have
also been shown to be induced by cellular stress (in par-
ticular endoplasmatic reticulum stress) [37-41]. These
data suggest that upregulation of stress-responsive tran-
scription factors is a common theme during late stage
chondrogenic differentiation in micromass culture. Since
Atf3 transcript levels display similar upregulation during
chondrocyte differentiation in vivo, this pattern does not
appear to be an artifact of the micromass culture system,
but to reflect the physiological processes of cartilage
development.
ATF2 and CREB, the prototype members of the ATF-CREB
family, have been shown to play crucial roles in chondro-
cyte cell cycle gene expression and proliferation [42,43].
While their activities are essential to ensure adequate rates
of proliferation, physiological bone development also
requires regulated cell cycle exit and onset of postmitotic
chondrocyte differentiation. These requirements necessi-
tate tight control of ATF2 and CREB activity that can be
achieved through several mechanisms. For example, both
transcription factors are regulated by posttranslational
modifications such as phosphorylation. Changes in phos-
phorylation status could therefore repress their activity
when chondrocytes exit the proliferative phase. For exam-
ple, we and others have shown that extracellular signals
such as Transforming Growth Factor β, Parathyroid Hor-
mone-related Peptide and prostaglandins induce phos-
phorylation of ATF2 and CREB in chondrocytes,
respectively [10,13,44]. Our data presented here also sug-
gest that Atf2 and Creb1 mRNA levels do not change dur-
ing chondrocyte differentiation, suggesting that they are
regulated at the posttranscriptional level (e.g. through
phosphorylation as discussed above and/or by regulation
of protein stability). Another possibility to limit ATF2/
CREB activity is the expression of transcriptional repres-
sors that compete with them for binding elements on tar-
get genes. One such repressor is ATF3 [26].
Our data show that Atf3 mRNA expression is markedly
upregulated during chondrocyte differentiation in a three-
dimensional micromass culture system in vitro and in
mouse embryonic tibiae in vivo. In addition, Atf3  is
strongly induced in response to cytochalasin D, an actin-
modifying drug that induces early [34,35,45,46] and late
(Woods and Beier, in prep.) chondrocyte differentiation.
Our transient transfection assays demonstrate that the
induction of Atf3 expression by cytochalasin D occurs, at
least in part, at the transcriptional level; however, induc-
tion of mRNA levels is markedly higher than stimulation
of promoter activity. This could be due to posttranscrip-
tional mechanisms such as increased mRNA stability as
has been described for Atf3  before [47]. Alternatively,
transcriptional activation of the endogenous Atf3  gene
through promoter/enhancer elements not present in our
reporter plasmid is possible.
The expression pattern of Atf3 is therefore consistent with
a function during cell cycle exit and terminal differentia-
tion. Furthermore, our data suggest that ATF3 represses
CRE-dependent transcription, for example the activity of
the cyclin D1 and cyclin A promoters. We have shown ear-
lier that the activities of these promoters correlates with
the corresponding protein levels in chondrocytes [11-13].
Induction of ATF3 should therefore result in reduced lev-
els of these cyclins and other ATF2/CREB targets. The cyc-
lin A promoter showed a much stronger response to ATF3
overexpression than the cyclin D1 promoter and the CRE
reporter. The most plausible explanation for this differ-
ence is that the cyclin A promoter, in addition to direct
regulation through the CRE, is also controlled by
upstream cell cycle proteins such as cyclin D1 and E2F
[48,49]. Reduced cyclin D1 levels and E2F activity in
response to ATF3 overexpression could therefore contrib-
ute to the observed strong downregulation of cyclin A
transcription by ATF3.
Mutation of the CRE in the cyclin A promoter completely
abolished the response to ATF3 overexpression, providing
strong evidence that the effects of ATF3 on cyclin A tran-
scription are mediated by direct binding to the CRE. Inter-
estingly, overexpression of ATF3 repressed cyclin A
promoter more than mutation of CRE. This suggests that
binding of ATF3 to the CRE also suppresses the activity of
other elements in the promoter, for example the E2F
response element discussed above.
In growth plate physiology, Sox9 suppresses and Runx2
promotes chondrocyte hypertrophy. In this study, we
observed repression of Sox9 activity and enhancement of
Runx2 activity in response to ATF3 overexpression, in
agreement with the postmitotic role of ATF3 suggested by
us. However, the mechanism(s) involved remain to be
elucidated. One possibility is that ATF3, indirectly or
directly, regulates expression of Sox9 and/or Runx2, or
required cofactors. A second possibility is that ATF3 phys-
ically interacts with each or both of these factors, thereby
modulating their activity. Both Sox9 and Runx2 are
known to undergo protein-protein interactions with
many other transcription factors. For example, Sox9 has
been shown to interact with c-Maf [50], steroidogenic fac-
tor 1 [51] and β-catenin [52]. Runx2 has been shown toBMC Molecular Biology 2006, 7:30 http://www.biomedcentral.com/1471-2199/7/30
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interact with, among others, Nrf2 [53] and Smad [54] pro-
teins. Most notably, Runx2 has been demonstrated to
bind to ATF4, another member of the ATF/CREB family,
although this interaction appears to be indirect [55]. A
third possibility is that the effects of ATF3 on Sox9 and
Runx2 activity are secondary to ATF3's effect on cell cycle
progression. It has been shown that Runx2 activity fluctu-
ates throughout the cell cycle and is controlled by the cell
cycle machinery [56-59]. For example, cyclin D1 together
with cyclin-dependent kinase 4 has been shown to pro-
mote ubiquitination and degradation of Runx2 [60].
Repression of cyclin D1 expression by ATF3 would thus
result in stabilization of Runx2 and increased differentia-
tion. Our model for the effects of ATF3 on chondrocyte
cell cycle gene expression and Runx2 activity is illustrated
in Fig. 6. To our knowledge, no cell cycle control mecha-
nisms for Sox9 activity have been reported, but are con-
ceivable.
Conclusion
In summary, this study identifies ATF3 as a novel player in
the complex networks controlling growth plate chondro-
cyte proliferation and differentiation. Induction of Atf3
expression by differentiation stimuli is likely to contribute
to the coordination of cell cycle exit and hypertrophic dif-
ferentiation during endochondral bone growth. Analyses
of the in vivo roles of ATF3 in endochondral ossification
and identification of the physiological inducers and target
genes of ATF3 during skeletogenesis will be important
steps towards a better understanding of cartilage develop-
ment.
Methods
Materials
Timed-pregnant CD1 mice (embryonic day 11.5 [E11.5]
or E15.5) were obtained from Charles River. Real-time
PCR reagents were obtained from Applied Biosystems.
Cell culture reagents and the pcDNA3 plasmid were from
Invitrogen, and cytochalasin D was purchased from Calbi-
ochem. Fugene 6 was obtained from Roche, the dual luci-
ferase assay and the plasmid pRLCMV were from
Promega. The CRE reporter plasmid was from Stratagene.
The SOX9 reporter plasmid has been described [61]; the
RUNX2 reporter plasmid was constructed in a similar
fashion (8 copies of a Runx2 binding site cloned upstream
of a minimal osteocalcin promoter in pGl3basic
[Promega]). The Atf3 promoter plasmid [23], the ATF3
expression plasmid [62], the cyclin D1 promoter plasmid
-1745CD1Luc [63] and the cyclin A promoter plasmids
pcycAluc707 and pcycAluc707mut [64] plasmid were
generously provided by Drs. J. Schwartz (University of
Michigan), D. Steiner (University of Chicago), R. Pestell
(Georgetown University) and K. Oda (Science University
of Tokyo), respectively.
RNA isolation, microarray analyses and real-time PCR
Sample generation, RNA isolation, microarrays and bioin-
formatics analyses for these data have been described
recently [33]. For microdissections, embryonic day 15.5
tibiae were dissected into the resting/proliferating, pre-
hypertrophic and hypertrophic areas under a stereomicro-
scope, and RNA was isolated following the RNeasy ® Lipid
Tissue Extraction protocol from Qiagen (Mississauga).
RNA integrity was verified using the Agilent 2100 Bioana-
lyzer. Real-time PCR was performed as described, using
Assays-on-Demand (Applied Biosystems) and Gapdh for
standardization [33,34,65]. All reactions were run in
quadruplicate from at least three independent experi-
ments.
Micromass cultures and primary chondrocyte cultures
Micromass cultures from E11.5 mouse limb buds and iso-
lation of primary murine chondrocytes from E15.5 long
bones were performed as recently described [33,66].
Micromass cultures were differentiated for 15 days, and
samples were harvested every three days for RNA isola-
tion. Primary chondrocytes were plated in monolayer cul-
ture in medium containing 10 % fetal bovine serum and
Model for ATF3 action in chondrocyte differentiation Figure 6
Model for ATF3 action in chondrocyte differentia-
tion. We suggest that induction of ATF3 by differentiation 
stimuli antagonizes the CRE-dependent expression of cyclin 
D1 and cyclin A, which are induced by mitogenic stimuli 
through ATF2 and CREB. Reduced cyclin-dependent kinase 
activity and hypophosphorylation of pocket proteins in 
response to ATF3 upregulation then results both in cell cycle 
exit and in increased activity of Runx2, promoting chondro-
cyte differentiation.
mitogenic stimuli
differentiation signals
ATF2/CREB
ATF3
cyclin D1, A
cell cycle progression
Runx2BMC Molecular Biology 2006, 7:30 http://www.biomedcentral.com/1471-2199/7/30
Page 9 of 11
(page number not for citation purposes)
incubated for 24 hours with DMSO (control) or 1 μM
cytochalasin D before harvest for RNA as described [35].
Transient transfections and luciferase assays
Primary chondrocytes in monolayer culture were tran-
siently transfected using Fugene 6 as described [14,35,67].
For Atf3 promoter analyses, cells were transfected with the
Atf3 promoter plasmid and pRLCMV for standardization.
After transfection, cells were incubated with DMSO or 1
μM cytochalasin D for 24 hours before harvesting for luci-
ferase assays. For cotransfections, cells were transfected
with the respective promoter plasmid (cyclin D1, cyclin A
or the CRE, SOX9 or RUNX2 reporters), pRLSV40 and
empty expression vector (pcDNA3) or the ATF3 expres-
sion vector. Cells were harvested 24 hours after transfec-
tion. Firefly luciferase activity was determined and
normalized to Renilla luciferase activity. All data shown
present averages and SEM from three independent experi-
ments done in quadruplicate each.
Statistical analyses
Statistical significance of real-time PCR and luciferase
results was determined by two-way ANOVA with Bonfer-
roni post-test using GraphPad Prism version 3.00 for Win-
dows, GraphPad Software, San Diego California USA.
Abbreviations
ATF, activating transcription factor; CRE, cyclic AMP
response element, CREB, CRE-binding protein; PCR,
polymerase chain reaction
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